University of Worcester Worcester Research and Publications

Pharmacology, Systematic Review and Recent Clinical Trials of Metadoxine

Di Miceli, Mathieu ORCID: and Gronier, B. (2018) Pharmacology, Systematic Review and Recent Clinical Trials of Metadoxine. Reviews on recent clinical trials, 13 (2). pp. 114-125. ISSN 1876-1038

[img] Text
Di Miceli and Gronier 2018 - Pharmacology, Systematic Review and Recent Clinical Trials of Metadoxine - RRCT.pdf - Published Version
Restricted to Repository staff only

Download (2MB) | Request a copy



Metadoxine is composed of pyroglutamic acid and vitamin B6. Administrations of metadoxine are indicated in cases of acute alcohol intoxication or in chronic alcoholism.


To reference all available clinical trials investigating the effects of metadoxine on humans. A focus was put on alcohol intoxication and chronic alcoholism, alcohol abstinence and survival rates. Adverse events were also taken into consideration. Finally, potential roles of metadoxine in treating disorders of the central nervous system will be assessed.


PRISMA guidelines were followed. Computerised literature searches were performed in July 2017 to retrieve all clinical trials investigating metadoxine from the MEDLINE®, the European Union Clinical Trials Register and the databases, using the following equation: "metadoxine". Inclusion criteria were all published clinical trials investigating metadoxine in humans, regardless of outcome measures. Exclusion criteria were articles not abstracted, studies, studies in rodents, retrospective studies and reviews.


Sixteen studies were included. Evidence suggests that metadoxine appears safe to use, as it rarely induced adverse events (reported in 7 out of the 7 studies measuring safety/tolerability). Moreover, metadoxine seems efficient in treating acute alcohol intoxication (2/2 studies) as well as improving liver functions following chronic alcoholism (4/5 studies). Finally, currently on-going clinical trials will reveal if metadoxine could be indicated in attention deficit and hyperactivity disorders as well as fragile X syndrome.


Metadoxine appears safe to use and seems efficient to improve liver functions following alcohol-related diseases. Further clinical trials will be necessary to determine if metadoxine can be promising for treating brain disorders. PROSPERO registration number: CRD42017072964.

Item Type: Article
Additional Information:

The full-text cannot be supplied for this item. Please check availability with your local library or Interlibrary Requests Service.

Uncontrolled Discrete Keywords: ADHD, alcoholism, clinical trials, fragile x syndrome, metadoxine, systematic review
Divisions: College of Health, Life and Environmental Sciences > School of Science and the Environment
Related URLs:
Depositing User: Mathieu Di Miceli
Date Deposited: 06 Oct 2021 11:17
Last Modified: 07 Dec 2021 16:53

Actions (login required)

View Item View Item
Worcester Research and Publications is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.